CoChat

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease

Open access
Mikocka-Walus, Antonina, Fielder, Andrea, Prady, Stephanie L, Esterman, Adrian J, Knowles, Simon, Andrews, Jane M · 2017 · Cochrane Database of Systematic Reviews
Cited by 42

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Symptoms of anxiety and depression are common in inflammatory bowel disease (IBD). Antidepressants are taken by approximately 30% of people with IBD. However, there are no current guidelines on treating co-morbid anxiety and depression in people with IBD with antidepressants, nor are there clear data on the role of antidepressants in managing physical symptoms of IBD. OBJECTIVES: The objectives were to assess the efficacy and safety of antidepressants for treating anxiety and depression in IBD, and to assess the effects of antidepressants on quality of life (QoL) and managing disease activity in IBD. SEARCH METHODS: We searched MEDLINE; Embase, CINAHL, PsycINFO, CENTRAL, and the Cochrane IBD Group Specialized Register from inception to 23 August 2018. Reference lists, trials registers, conference proceedings and grey literature were also searched. SELECTION CRITERIA: Randomised controlled trials (RCTs) and observational studies comparing any type of antidepressant to placebo, no treatment or an active therapy for IBD were included. DATA COLLECTION AND ANALYSIS: Two authors independently screened search results, extracted data and assessed bias using the Cochrane risk of bias tool. We used the Newcastle-Ottawa Scale to assess quality of observational studies. GRADE was used to evaluate the certainty of the evidence supporting the outcomes. Primary outcomes included anxiety and depression. Anxiety was assessed using the Hospital Anxiety and Depression Scale (HADS) or the Hamilton Anxiety Rating Scale (HARS). Depression was assessed using HADS or the Beck Depression Inventory. Secondary outcomes included adverse events (AEs), serious AEs, withdrawal due to AEs, quality of life (QoL), clinical remission, relapse, pain, hospital admissions, surgery, and need for steroid treatment. QoL was assessed using the WHO-QOL-BREF questionnaire. We calculated the risk ratio (RR) and corresponding 95% confidence intervals (CI) for dichotomous outcomes. For continuous outcomes, we calculated the mean difference (MD) with 95% CI. A fixed-effect model was used for analysis. MAIN RESULTS: We included four studies (188 participants). Two studies were double-blind RCTs, one was a non-randomised controlled trial, and one was an observational retrospective case-matched study. The age of participants ranged from 27 to 37.8 years. In three studies participants had quiescent IBD and in one study participants had active or quiescent IBD. Participants in one study had co-morbid anxiety or depression. One study used duloxetine (60 mg daily), one study used fluoxetine (20 mg daily), one study used tianeptine (36 mg daily), and one study used various antidepressants in clinical ranges. Three studies had placebo controls and one study had a no treatment control group. One RCT was rated as low risk of bias and the other was rated as high risk of bias (incomplete outcome data). The non-randomised controlled trial was rated as high risk of bias (random sequence generation, allocation concealment, blinding). The observational study was rated as high methodological quality, but is still considered to be at high risk of bias given its observational design.The effect of antidepressants on anxiety and depression is uncertain. At 12 weeks, the mean anxiety score in antidepressant participants was 6.11 + 3 compared to 8.5 + 3.45 in placebo participants (MD -2.39, 95% -4.30 to -0.48, 44 participants, low certainty evidence). At 12 months, the mean anxiety score in antidepressant participants was 3.8 + 2.5 compared to 4.2 + 4.9 in placebo participants (MD -0.40, 95% -3.47 to 2.67, 26 participants; low certainty evidence). At 12 weeks, the mean depression score in antidepressant participants was 7.47 + 2.42 compared to 10.5 + 3.57 in placebo participants (MD -3.03, 95% CI -4.83 to -1.23, 44 participants; low certainty evidence). At 12 months, the mean depression score in antidepressant participants was 2.9 + 2.8 compared to 3.1 + 3.4 in placebo participants (MD -0.20, 95% -2.62 to 2.22, 26 participants; low certainty evidence).The effect of antidepressants on AEs is uncertain. Fifty-seven per cent (8/14) of antidepressant participants group reported AEs versus 25% (3/12) of placebo participants (RR 2.29, 95% CI 0.78 to 6.73, low certainty evidence). Commonly reported AEs include nausea, headache, dizziness, drowsiness, sexual problems, insomnia, fatigue, low mood/anxiety, dry mouth, muscle spasms and hot flushes. None of the included studies reported any serious AEs. None of the included studies reported on pain.One study (44 participants) reported on QoL at 12 weeks and another study (26 participants) reported on QoL at 12 months. Physical, Psychological, Social and Environmental QoL were improved at 12 weeks compared to placebo (all low certainty evidence). There were no group differences in QoL at 12 months (all low certainty evidence). The effect of antidepressants on maintenance of clinical remission and endoscopic relapse is uncertain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd012680

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 34

  1. Australian Medicines Handbook Pty, 2012, Duloxetine
  2. Baumeister, 2011, Psychological and pharmacological interventions for depression in patients with coronary artery disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008012.pub3 · DOI · Paper page
  3. Baumeister, 2014, Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review, Diabetic Medicine, 31, 773, 10.1111/dme.12452 · DOI · Paper page
  4. Bernstein, 2011, A prospective population-based study of triggers of symptomatic flares in IBD, American Journal of Gastroenterology, 105, 1994, 10.1038/ajg.2010.140 · DOI · Paper page
  5. Brown, 2005, A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study, Biological Psychiatry, 58, 865, 10.1016/j.biopsych.2005.04.030 · DOI
  6. D'Haens, 2008, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet, 371, 660, 10.1016/S0140-6736(08)60304-9 · DOI · Paper page
  7. Daghaghzadeh, 2015, Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study, Journal of Research in Medical Sciences, 20, 595, 10.4103/1735-1995.165969 · DOI · Paper page
  8. Deeks, 2001, Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis, 10.1002/9780470693926.ch15 · DOI · Paper page
  9. Deeks, 2011. Available from www.cochrane-handbook.org, Chapter 9: Analysing data and undertaking meta-analyses
  10. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  11. Feagan, 2007, The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients, American Journal of Gastroenterology, 102, 794, 10.1111/j.1572-0241.2007.01094.x · DOI · Paper page
  12. Gartlehner, 2007, Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
  13. Gartlehner, 2011, Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review
  14. Gordon, 2013, Antidepressants for depression during pregnancy, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010710 · DOI
  15. Guemei, 2008, Do desipramine [10,11-dihydro-5-[3-(methylamino) propyl]-5H-dibenz[b,f]azepine monohydrochloride] and fluoxetine [N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan-1-amine] ameliorate the extent of colonic damage induced by acetic acid in rats?, Journal of Pharmacology and Experimental Therapeutics, 327, 846, 10.1124/jpet.108.141259 · DOI
  16. Haapamaki, 2013, Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics, Scandinavian Journal of Gastroenterology, 48, 42, 10.3109/00365521.2012.743584 · DOI · Paper page
  17. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  18. Higgins, 2011. Available from www.cochrane-handbook.org, Chapter 8: Assessing risk of bias in included studies
  19. Krommydas, 2005, Therapeutic value of antidepressants in asthma, Medical Hypotheses, 64, 938, 10.1016/j.mehy.2004.06.036 · DOI
  20. Loftus, 2004, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterology, 126, 1504, 10.1053/j.gastro.2004.01.063 · DOI · Paper page
  21. Maes, 2001, The immunoregulatory effects of antidepressants, Human Psychopharmacology, 16, 95, 10.1002/hup.191 · DOI · Paper page
  22. Maunder, 2008, The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence, Current Molecular Medicine, 8, 247, 10.2174/156652408784533832 · DOI · Paper page
  23. Mikocka-Walus, 2007, "It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease, BMC Gastroenterology, 7, 38, 10.1186/1471-230X-7-38 · DOI · Paper page
  24. Mikocka-Walus, 2009, Can antidepressants influence the course of inflammatory bowel disease (IBD)? The current state of research, European Gastroenterology and Hepatology Review, 5, 48
  25. Mikocka-Walus, 2017, Fluoxetine for maintenance of remission and to improve quality of life in patients with Crohn's disease: a pilot randomized placebo-controlled trial, Journal of Crohn's and Colitis, 11, 509
  26. Nigro, 2001, Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance, Journal of Clinical Gastroenterology, 32, 66, 10.1097/00004836-200101000-00015 · DOI · Paper page
  27. O'Brien, 2006, Antidepressant therapy and C-reactive protein levels, British Journal of Psychiatry, 188, 449, 10.1192/bjp.bp.105.011015 · DOI · Paper page
  28. Ritter, 2015, Rang & Dale's Pharmacology
  29. Rocchi, 2012, Inflammatory bowel disease: a Canadian burden of illness review, Canadian Journal of Gastroenterology, 26, 811, 10.1155/2012/984575 · DOI · Paper page
  30. Shorter, 2009, The history of lithium therapy, Bipolar Disorders, 11, 4, 10.1111/j.1399-5618.2009.00706.x · DOI · Paper page
  31. Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
  32. Szuster-Ciesielska, 2003, In vitro immunoregulatory effects of antidepressants in healthy volunteers, Polish Journal of Pharmacology, 55, 353
  33. Varghese, 2006, Antidepressants attenuate increased susceptibility to colitis in a murine model of depression, Gastroenterology, 130, 1743, 10.1053/j.gastro.2006.02.007 · DOI
  34. Williams, 2000, A systematic review of newer pharmacotherapies for depression in adults: evidence report summary, Annals of Internal Medicine, 132, 743, 10.7326/0003-4819-132-9-200005020-00011 · DOI · Paper page

Cited by

See all 42

Metadata

Authors
Mikocka-Walus, A., Fielder, A., Prady, S. L., Esterman, A. J., Knowles, S., & Andrews, J. M.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2017-07-06
Volume
4
Pages
CD012680-CD012680
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2727792274
Cited by
42
References
25
FWCI
1.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. https://app.cochat.ai/papers/10.1002/14651858.cd012680
The paper
Mikocka-Walus, A., Fielder, A., Prady, S. L., Esterman, A. J., Knowles, S., & Andrews, J. M. (2017). Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd012680

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.